
- Drug Topics April 2019
- Volume 163
- Issue 4
Bayer, J&J Pay $775 Million in Xarelto Lawsuits
More than 25,000 lawsuits cite uncontrollable and irreversible bleeding and death.
Bayer AG and Johnson & Johnson have agreed to jointly settle $775 million in lawsuits over their Xarelto (rivaroxaban) blood thinner.
More than 25,000 plaintiffs have accused the drug makers of failing to warn of the bleeding risks associated with Xarelto and believe that their injuries could have been prevented with adequate information.
Trending:
Injuries cited in the cases include the development of uncontrollable and irreversible bleeding, which has led to severe injuries and deaths. Anticoagulants as a category were linked with about 3,000 deaths in 2016, according to the Institute for Safe Medication Practices.
Xarelto has proven to be Bayer’s best-selling drug, earning $4.07 billion (€3.6 billion). J&J reported $2.47 billion earned from the drug.
Articles in this issue
over 6 years ago
Profiles of Four Travel Health Clinicsover 6 years ago
Prucalopride Approved for Idiopathic Constipationover 6 years ago
Clinical Pharmacists Are Integral Team Members in PCMHsover 6 years ago
Four Strategies for Reacting to Rude Customersover 6 years ago
Resources for Getting Started with Telepharmacyover 6 years ago
Harnessing Technology to Enhance Diabetes Adherenceover 6 years ago
Telepharmacy's New Frontiers Expand Business OpportunitiesNewsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.